STACY UTTON: Open Payments
NPI 1912351404 · VIRGINIA BEACH, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,456 in 62 payments from 16 companies in 2025. Trend: 2023 $1,990 · 2024 $1,905 · 2025 $1,456
Food & beverage: $1,456
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $670 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $196 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| Gilead Sciences, Inc. | 4 | $82 |
| Ardelyx, Inc. | 3 | $68 |
| Janssen Biotech, Inc. | 3 | $55 |
| Celltrion USA Inc. | 2 | $53 |
| Intercept Pharmaceuticals, Inc. | 2 | $51 |
| PFIZER INC. | 2 | $36 |
| QOL Medical, LLC | 1 | $26 |
Products named: SKYRIZI, ENTYVIO, RINVOQ, LINZESS, XIFAXAN, IBSRELA, TREMFYA, VEGZELMA.
Industry payments across VA — which companies pay providers there.
